(Updates with Kenvue's response to a request for comment in the last paragraph.)
A federal appeals court on Monday vacated a district court's earlier dismissal of plaintiff claims that they were not warned that prenatal ingestion of Kenvue's (KVUE) Tylenol and its generic equivalents could cause autism spectrum disorder and attention-deficit/hyperactivity disorder.
The two cases impacted by the appeals court ruling were remanded for further proceedings.
"The procedural ruling today does not change the fact that credible, independent science shows no proven link between taking acetaminophen and autism or attention deficit hyperactivity disorder," Kenvue said in a statement to. "Science matters, and we stand with the many public health and medical professionals who have reviewed the science on this topic and agree. We now have another opportunity to show that the plaintiffs' experts' opinions are unreliable and should not be allowed in this case. We stand behind the safety of our product and will continue to defend these cases."
Price: $19.18, Change: $-0.31, Percent Change: -1.57%